Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
For direct API integration and via third-party provider OpenRouter, MiniMax M2.7 maintains a cost-leading price point of 0.30 dollars per 1 million input tokens and 1.20 dollars per 1 million output ...
Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...
MiniMax instructed the development of a research agent harness for an 'internal version of MiniMax M2.7' in order to develop the production version of MiniMax M2.7. The constructed agent harness can ...
Self-evolving AI is no longer a distant concept, as demonstrated by MiniMax M2.7’s remarkable ability to improve itself without human input. By using iterative self-assessment cycles, this model ...
AMD’s Ryzen AI Max+ 395 Strix Halo processor packs a lot of power into a mobile chip designed for laptops and mini PCs. With integrated graphics that rivals a discrete GPU, it offers an efficient ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results